Excellence is just the beginning.


French German Italian Portuguese Russian

SBRT for Localized Prostate Cancer Study

Clinical Trial Title: 
A prospective evaluation of multi-parametric magnetic resonance imaging (mpMRI) guided stereotactic body radiation treatment for localized prostate cancer.
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Dian Wang, MD, PhD
Clinical Trial Protocol Description: 

A type of imaging called multi-parametric magnetic resonance imaging (mpMRI) has been approved to detect aggressive, high-grade, invasive prostate cancer. This is considered the standard care for prostate cancer. An MRI is a type of scan that uses magnets, radio waves, and a computer to produce images of body structures. The purpose of this study is to evaluate the effects, good and/or bad, of using mpMRI to guide high-dose radiation treatment for prostate cancer.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of prostate cancer within 1 year.
  • Have no distant metastases or regional lymph node involvement.
  • Have no use of finasteride within 30 days.
  • Have no use of dutasteride within 90 days.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Genitourinary Cancers
Contact Phone: 
(312) 942-0836
Contact Name: 
Adrianne Kajmowicz, RN, BSN